SCHEMBL22200529

SCHEMBL22200529

C[S+]([O-])c1ncc2cc(Br)c(=O)n(C3CC3)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND1 P24385 11/20 0.49
CDK4 P11802 9/20 0.49
CDK2 P24941 9/20 0.49
CCNA2 P20248 5/20 0.49
CCND3 P30281 4/20 0.47
CCND2 P30279 3/20 0.47
FGFR1 P11362 3/20 0.42
FGFR2 P21802 3/20 0.42
FGFR4 P22455 3/20 0.42
FGFR3 P22607 3/20 0.42
CCNA1 P78396 2/20 0.42
PIK3CA P42336 6/20 0.42
ALDH1A1 P00352 3/20 0.37
CYP1A2 P05177 3/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 2/20 0.35
MAPK1 P28482 1/20 0.35
CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4830604 0.95 CCND1 (0.55) CCND1CDK4CDK2CCNA2CCND3
SCHEMBL31153370 0.95 CCND1 (0.55) CCND1CDK4CDK2CCNA2CCND3
SCHEMBL4833696 0.94 CCND1 (0.54) CCND1CDK4CDK2CCNA2CCND3
SCHEMBL4828668 0.81 CDK2 (0.53) CCND1CDK4CDK2CCNA2CCND3
SCHEMBL4826681 0.81 CCND1 (0.48) CCND1CDK4CDK2CCNA2CCND3
SCHEMBL13553975 0.80 WEE1 (0.38) CCND1CDK4CDK2CCNA2FGFR1
SCHEMBL4835866 0.80 CCND1 (0.54) CCND1CDK4CDK2CCNA2CCND3
SCHEMBL29507751 0.80 CDK2 (0.40) CCND1CDK4CDK2CCNA2CCND3
SCHEMBL4835897 0.78 CCND1 (0.47) CCND1CDK4CDK2CCNA2CCND3
SCHEMBL22015971 0.78 NUAK1 (0.56) CCND1CDK4CDK2CCNA2CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed